Ratings Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E. Other stock markets 03:59:35 2024-04-23 pm EDT			5-day change	1st Jan Change
1.89 ^CAD	+2.16%		+4.42%	-11.68%

Apr. 10	Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	MT
Apr. 10	Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
THERATECHNOLOGIES INC.	-11.68%	63.57M	-
CSL LIMITED	-2.86%	87.37B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+4.08%	41.01B	A-
BIOGEN INC.	-25.35%	28.08B	B-
UCB	+54.18%	24.72B	A
BIOMARIN PHARMACEUTICAL INC.	-4.52%	17.47B	C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.09%	11.69B	B
INCYTE CORPORATION	-17.77%	11.6B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.10%	11.56B	D+
SWEDISH ORPHAN BIOVITRUM AB	+1.42%	8.44B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes